Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omeros reports record earnings, navigates FDA challenges for growth

Omeros showcased strong financial performance, a robust pipeline, and strategic partnerships in Q4 2022.
While challenges like FDA concerns and tight timelines exist, the company is well-positioned to capitalize on growth opportunities.
With a focus on advancing key programs and maintaining financial stability, Omeros aims to deliver value to shareholders and patients.

Omeros reports Q1 loss, progresses in key programs amid challenges

Omeros' Q1 2023 performance reflected a shift from net income to a significant loss, driven by increased expenses and reduced income, while maintaining a strong cash position and positive sales figures for OMIDRIA.
The company showcased strengths in diversified revenue streams, progress in key clinical programs, and inclusion in the Russell 3000 Index, signaling growth potential and market recognition.
Challenges in regulatory processes, market competition, and resource allocation were evident, requiring strategic navigation and operational efficiency to overcome hurdles and drive future success.
Amidst challenges, Omeros identified opportunities in expanding royalties, advancing clinical programs, exploring new indications, and leveraging immuno-oncology advancements to drive future growth and innovation.

Omeros reports Q2 loss, eyes FDA decisions and revenue growth

Omeros faces challenges with debt maturity and regulatory approvals but benefits from strong revenue streams
The company's pipeline shows promise in addressing various diseases, with a focus on high unmet medical needs
Opportunities lie in expanding revenue through OMIDRIA and advancing key drug candidates towards approval

Omeros reports Q3 losses, highlights pipeline strength and regulatory progress

Omeros demonstrated a mixed financial performance in Q3 2023 but showcased strength in its pipeline and strategic alignment with regulatory authorities.
Challenges persist in financial metrics and regulatory timelines, necessitating a balance between innovation and operational efficiency.
The company's opportunities in immuno-oncology and stable revenue streams position Omeros for future growth and impact in the biopharmaceutical landscape.

Omeros extends cash runway, advances key pipeline candidates for growth

Omeros demonstrated improved financial performance, securing additional funding and advancing key pipeline candidates, positioning the company for future growth.
While facing challenges in regulatory processes and anticipated losses, Omeros' strategic priorities and innovative pipeline offer opportunities for long-term success.
Management's focus on financial stability, operational efficiency, and product differentiation underscores Omeros' commitment to delivering value to shareholders and patients.

Omeros reports increased net loss but optimistic about pipeline progress

Omeros faced a significant increase in net loss in Q1 2024 but maintains a strong financial position with $230.3 million in cash and investments.
The company's development programs, especially OMS906, show promise with positive trial results and potential milestone payments tied to OMIDRIA sales.
While challenges like regulatory approvals and competition exist, Omeros is optimistic about its pipeline and aims for Phase III trials and regulatory successes.
Overall, Omeros is strategically positioned to leverage opportunities for growth and diversification in the biopharmaceutical market.

Omeros reports improved Q3 performance with promising drug developments

Omeros' Q3 2024 performance showed improvements in net loss and strategic financial decisions.
The company's strengths lie in potential revenue streams from OMIDRIA sales and positive trial data.
Challenges include regulatory hurdles and managing costs amidst multiple development programs.
Opportunities exist in sales growth, milestone payments, and advancing key drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omeros Corporation: The Thesis Was Playing Out Before COVID-19 Hit

Omeros closed out Q4 2019 with an excellent earnings report.

Omeros' Tumultuous March

The company reported full-year 2019 operating results and a separate update from the pipeline.

Here's Why Omeros Corporation Stock Rose as Much as 46.5% Today

Omeros Corporation (OMER) CEO Greg Demopulos on Q4 2019 Results - Earnings Call Transcript

Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates

Omeros: Competition Is In Trouble

Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma

Single-arm trial data for narsoplimab isn't nearly as exciting as it used to be.

Here's Why Omeros Stock Is Tumbling Today

Shares of thinly-traded small-cap biopharma Omeros Corporation (NASDAQ: OMER) are advancing Wednesday following a positive readout from a pivotal Phase 3 study of its investigational asset narsoplimab.

Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab

Shares of Omeros Corp. OMER, +8.08% rallied 7% in morning trading on positive data for narsoplimab, its experimental therapy for a complication that can occur for patients undergoing stem cell transplants.

Omeros stock gains on transplant drug data

Omeros: Bull Thesis Cracked And Bleeding But Still Intact

Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2019 Results - Earnings Call Transcript

Insperity

Find out why these stocks missed out on the market rally.

Why NVR, Insperity, and Omeros Slumped Today

Today, we revisit intriguing biotech concern Omeros who posted better than expected Q2 revenue growth late last week.

Omeros: Moving Forward

Omeros Corporation (OMER) CEO Greg Demopulos on Q2 2019 Results - Earnings Call Transcript

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know

Shares of the thinly traded small-cap biotech Omeros Corporation (NASDAQ: OMER) were advancing strongly Thursday.

Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment

Omeros' Omidria revenue appears to be on track through its Q1, 2019 report with solid prognosis going forward.

Omeros: Full Steam Ahead

Omeros' (OMER) CEO Greg Demopulos on Q1 2019 Results - Earnings Call Transcript

Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know

Omeros is a clinical stage biotech that is in the midst of a pullback. I expect it to recover and will be watching for healthy returns once one of its Phase 3 candidates hauls in an FDA or EMA approval.

News for Omeros Stock (OMER)